腹腔热灌注联合静脉化疗治疗晚期卵巢癌的临床观察

目的:探讨腹腔热灌注联合静脉化疗治疗晚期卵巢癌的疗效及不良反应。方法:将2005年5 月～2009年2 月收治的90例经病理学或细胞学确诊的Ⅲ～Ⅳ期卵巢癌患者采用信封法随机分为腹腔热灌注联合静脉化疗组50例（治疗组）和单纯静脉化疗组40例（对照组），治疗组采用顺铂腹腔热灌注联合紫杉醇静脉化疗，对照组采用紫杉醇联合顺铂静脉化疗，观察两组的肿瘤控制率、腹水控制率及不良反应。结果:两组的肿瘤控制率（CR+PR）分别为72% 和47.5% ，差异具有统计学意义（P=0.018），两组的腹水控制率（CR+PR）分别为80% 和50% ，差异具有统计学意义（P=0.014），两组Ⅲ～Ⅳ度不良反应发生率分别为38% 和40% ，差异无统计学意义（P=0.847）。 结论:腹腔热灌注联合静脉化疗治疗晚期卵巢癌的疗效优于单纯静脉化疗，且不良反应能够耐受，值得临床推广。 

The Study of Intraperitoneal Hyperthermal Chemotherapy Combined with Intravenous Chemotherapy in the Treatment of Advanced Ovarian Carcinoma

Objective: To explore the effects and side effects of intraperitoneal hyperthermal chemotherapy combined with intravenous chemotherapy in the treatment of advanced ovarian carcinoma. Methods:Ninety patients with advanced ovarian carcinoma were selected and divided randomly into two groups. There were50cases in the treatment group, re -ceiving intraperitoneal hyperthermal chemotherapy with DDP and intravenous chemotherapy with PTX. There were 40 cases in the control group, receiving intravenous chemotherapy with PTX and DDP. The tumortumor control rate, the ascites control rate and the main side effects were observed in the two groups. Results: The control rate was72% in the treatment group and 47.5% in the control group, with a significant difference between the two groups (P = 0.018 ). The ascites control rate was 80% in the treatment group and50% in the control group, with a significant difference between the two groups (P = 0.014 ). The rates of the main side effects in the two groups were 38% and 40%, respectively, without significant differ-ences (P = 0.847 ). Conclusion:The effect of intraperitoneal hyperthermal chemotherapy combined with intravenous chemo-therapy on advanced ovarian carcinoma is better than that of intravenous chemotherapy alone and the main side effects are tolerable.